Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TJ08 is a 1,2,5-trisubstituted benzimidazole derivative with anticancer properties that effectively induces G1/S phase blockade while promoting apoptotic effects in a variety of cancer cells.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 397.00 | |
5 mg | In stock | $ 970.00 | |
10 mg | In stock | $ 1,180.00 | |
25 mg | In stock | $ 1,580.00 | |
50 mg | In stock | $ 1,980.00 | |
100 mg | In stock | $ 2,500.00 |
Description | TJ08 is a 1,2,5-trisubstituted benzimidazole derivative with anticancer properties that effectively induces G1/S phase blockade while promoting apoptotic effects in a variety of cancer cells. |
In vitro | TJ08 (1-10 μM; 24 hours) induces apoptosis by altering mitochondrial membrane potential, triggering S-phase arrest, halting cancer cell progression, and causing upregulation of caspase activation and downregulation of anti-apoptotic BCl2 protein [1]. |
Molecular Weight | 405.38 |
Formula | C22H16FN3O4 |
CAS No. | 2924274-19-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
TJ08 2924274-19-9 Apoptosis inhibitor inhibit